Randomized trial · people

Semaglutide: 6.5% vs 8.0% had a major heart event in SELECT

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with heart disease and excess weight but no diabetes, weekly semaglutide 2.4 mg led to fewer heart-related deaths, heart attacks and strokes than placebo, and more people stopped it because of side effects.

Kind
Randomized trial
Studied in
People
Number studied
17604
Published
2023
Journal
N Engl J Med

What they tested

Does weekly semaglutide lower the risk of heart-related death, heart attack or stroke in people with heart disease and excess weight who do not have diabetes?

How the study was done

A double-blind, randomized, placebo-controlled trial at many centers in 17,604 adults aged 45 or older with existing heart disease, a body-mass index of 27 or greater and no diabetes. It compared once-weekly 2.4 mg semaglutide shots with placebo (a dummy shot), and average follow-up was 39.8±9.4 months.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

The main outcome was the first of three events: death from heart causes, a nonfatal heart attack or a nonfatal stroke. It happened in 569 of 8803 people (6.5%) on semaglutide and 701 of 8801 people (8.0%) on placebo. The hazard ratio, a measure of risk over time on semaglutide versus placebo, was 0.80, with a likely range running from 0.72 up to 0.90, and the gap was statistically significant (P<0.001). Side effects made 1461 people (16.6%) on semaglutide stop the treatment for good, compared with 718 (8.2%) on placebo.

What it doesn’t show

It included only people aged 45 or older who already had heart disease, so it does not show the effect in people without heart disease or in people with diabetes. It tested one dose, and the trial was funded by Novo Nordisk.

The paper

Lincoff et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023.

The compound

More studies on Semaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo